talkhealth Blog

MEDA Pharmaceuticals UK, suppliers of EpiPen^® and EpiPen^® Jr Auto-Injectors (0.3 and 0.15 mg adrenaline), has assured the Department of Health that it has adequate product supply to cover all patients requiring replacement adrenaline auto-injectors (AAI) with immediate effect.

This confirmation is made in light of the voluntary product recall of Anapen^® by Lincoln Medical which was announced on 23^rd May 2012.

EpiPen^® and EpiPen^® Jr Auto-Injectors (0.3 and 0.15 mg adrenaline) are used to treat signs and symptoms of a life-threatening allergic reaction (anaphylaxis), some of which include hives, redness of the skin, tightness in the throat, breathing problems and/or a decrease in blood pressure. A life-threatening allergic reaction (anaphylaxis) can be caused by triggers such as food, stinging and biting insects, medicines, latex, or even exercise.

Sufficient stock levels of EpiPen^® and EpiPen^® Jr Auto-Injectors (0.3 and 0.15 mg adrenaline) are available to cover all patients in the UK who require new AAIs.

Patient information and support materials are also available for patients requiring a switch in medication. For further stock and patient information enquiries please contact:

MEDA
Tel: +44 (0)845 460 0000
Fax: +44 (0)845 460 0002
Email: info@medapharma.co.uk

+1485

  

talkhealth

This is the talkhealth blog spot, where we post on a wide range of health conditions, topics, issues and concerns. We post when we see something that we believe is of interest to our visitors. Our posts do not reflect any particular view or standpoint of talkhealth, but are merely to raise attention and awareness.